Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Abstract

Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.K. Health Security Agency.).

MeSH Terms

2019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19COVID-19 VaccinesCase-Control StudiesChAdOx1 nCoV-19HumansImmunizationSecondarySARS-CoV-2Vaccine Efficacy

Affiliated Institutions

Anna Needs Neuroblastoma Answers US

Related Publications

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar‐On , Yair Goldberg , Micha Mandel +8 more

In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of c...

2021 New England Journal of Medicine 1205 citations

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Shabir A. Madhi , Vicky L. Baillie , Clare Cutland +48 more

A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Fou...

2021 New England Journal of Medicine 1301 citations

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Jamie Lopez Bernal , Nick Andrews , Charlotte Gower +12 more

Abstract Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (includ...

2021 BMJ 1367 citations

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas , Frederick J. Angulo , John M. McLaughlin +12 more

Following the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Healt...

2021 The Lancet 1722 citations

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. García-Beltrán , Evan C. Lam , Kerri St. Denis +12 more

Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spi...

2021 Cell 1520 citations

Publication Info

Year: 2022
Type: article
Volume: 386
Issue: 16
Pages: 1532-1546
Citations: 2155
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2155

OpenAlex

Influential

2057

CrossRef

Cite This

APA Style

                            
                                
                                    Nick Andrews, 
                                
                                    Julia Stowe, 
                                
                                    Freja Kirsebom
                                
                                et al.
                            
                            (2022). 
                            Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. 
                            New England Journal of Medicine
                            , 386
                            (16)
                            , 1532-1546.
                            https://doi.org/10.1056/nejmoa2119451
                        

Identifiers

DOI: 10.1056/nejmoa2119451
PMID: 35249272
PMCID: PMC8908811

Data Quality

Data completeness: 81%